Brian Torgerson, MD
Pain Medicine · Tulsa, OKNPI 1194928283
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.1%), other and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Nevro Corp. at 53.6% of the total. Reporting peaked in 2023 at $6,112 and has fallen 83.5% since, to $1,008 in 2025.
Across 292 payments — averaging $44.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$7K
- Vertiflex, Inc.$1K
- Boston Scientific$1K
- Collegium Pharmaceutical, Inc.$566
- AbbVie$388
- Abbott$338
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$630%
- Travel & lodging$1,0688%
- Food & beverage$6,83352%
- Other$5,15839%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 61 | $7,038 |
| Vertiflex, Inc. | 15 | $1,359 |
| Boston Scientific | 23 | $1,023 |
| Collegium Pharmaceutical, Inc. | 31 | $566 |
| AbbVie(2 entities) | 19 | $388 |
| Abbott | 20 | $338 |
| Medtronic(2 entities) | 17 | $321 |
| Scilex Pharmaceuticals Inc. | 13 | $232 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $206 |
| Averitas Pharma Inc. | 9 | $198 |
| Si-bone, Inc. | 3 | $191 |
| Saluda Medical Americas, Inc. | 7 | $157 |
| Forte Bio-pharma LLC | 8 | $139 |
| Pacira Therapeutics, Inc. | 4 | $123 |
| Arbor Pharmaceuticals, Inc. | 8 | $121 |
| Pfizer | 4 | $71 |
| Nalu Medical, Inc. | 2 | $65 |
| GRT US Holding, Inc. | 3 | $65 |
| Globus Medical | 3 | $64 |
| Amgen | 4 | $55 |
| Valinor Pharma, LLC | 3 | $53 |
| Biodelivery Sciences International, Inc. | 4 | $50 |
| Zyla Life Sciences, Inc. | 3 | $36 |
| SPR Therapeutics, Inc | 2 | $35 |
| Bioventus LLC | 2 | $34 |
| Eisai Inc. | 2 | $33 |
| Biogen | 1 | $26 |
| Zimvie Inc. | 1 | $21 |
| Stryker | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Vertex | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Medline Industries LP | 1 | $14 |
| MDD US Operations, LLC | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
| Spinal Simplicity, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$5,541
- Superion ISS$1,000
- Senza Spinal Cord Stimulation System$265
- Intracept$174
- Superion Indirect Decompression System$147
- Senza$140
- iFuse Implant$134
How this compares
$13,122 in reported general payments places this provider in the 85th percentile of 68 pain medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 183 | $136,435 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,669 | $48,711 |
| Buprenorphine | 180 | $36,566 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 827 | $25,917 |
| BotoxOnabotulinumtoxina | 18 | $21,852 |
| ZtlidoLidocaine | 21 | $9,313 |
| Pregabalin | 347 | $6,740 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 272 | $6,415 |
| Lidocaine | 59 | $5,455 |
| ButransBuprenorphine | 13 | $5,193 |
| Gabapentin | 371 | $4,565 |
| Tizanidine Hcl | 254 | $3,451 |
| Tramadol Hcl ErTramadol Hcl | 62 | $3,426 |
| Methocarbamol | 136 | $2,771 |
| Oxycodone Hcl | 188 | $2,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $566 | $136,435183 claims |
| AbbVieBotox | $388 | $21,85218 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $232 | $9,31321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 pain medicine providers in Oklahoma.
Other pain medicine in Tulsa
- Lam NguyenTulsa$11K
- Jayen PatelTulsa$10K
- Hugo SalgueroTulsa$10K
- Adam WallaceTulsa$8K
- Kenneth ReedTulsa$7K
- Ahmad KhattabTulsa$7K
- David DoTulsa$6K
- Emad Attallah-WasifTulsa$4K
- Leslie ChanTulsa$4K
- Chancen HallTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.